Status:

COMPLETED

Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Breast Cancer

Eligibility:

FEMALE

Phase:

PHASE2

Brief Summary

Primary Objective(s): * To compare the activity (progression-free survival \[PFS\]) of anastrozole in combination with lonafarnib to that of anastrozole in combination with placebo in subjects with h...

Eligibility Criteria

Inclusion

  • Postmenopausal women who have histologically-confirmed breast cancer with the following characteristics:
  • estrogen and/or progesterone receptor positive,
  • locally advanced disease
  • distant metastatic disease, stage 4
  • Subjects eligible for single-agent treatment with aromatase inhibitors for current disease.
  • Subjects taking biophosphonates are allowed if they begin bisphosphonate therapy AT LEAST two weeks prior to randomization.
  • Measurable disease (masses with clearly defined margins on radiological images and at least one diameter \>=20 mm\[\>=10 mm if spiral CT\]) or evaluable disease (masses with margins not clearly defined on radiological images or with no diameter \>= 20 mm). Subjects with bone disease only are permitted if disease is evaluable.
  • ECOG Performance Status of 0 or 1.
  • Sufficient bone marrow reserve.
  • Adequate hepatic and renal function: laboratory values within protocol requirements.

Exclusion

  • Subjects who have received more than one regimen of cytotoxic chemotherapy for advanced disease.
  • Subjects with with CLINICALLY APPARENT brain metastases or extensive visceral disease, including extensive hepatic involvement or pulmonary lymphangitic spread of tumor.
  • Subjects with prior treatments with FTIs.
  • Subjects with a known or suspected hypersensitivity to any excipients in the lonafarnib formulation (Providone, Poloxamer 188, croscarmellose sodium, silicon dioxide, and magnesium stearate).

Key Trial Info

Start Date :

December 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2009

Estimated Enrollment :

110 Patients enrolled

Trial Details

Trial ID

NCT00081510

Start Date

December 1 2003

End Date

May 1 2009

Last Update

April 15 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.